Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations

Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations Publisher Pubmed

Singh JA^{1, 2, 3} ; Kochhar S^{4, 5} ; Wolff J⁶ ; Atuire C⁷ ; Bhan A⁸ ; Emanuel E⁹ ; Faden R¹⁰ ; Ghimire P¹¹ ; Greco D¹² ; Ho C¹³ ; Moon S¹⁴ ; Shamsigooshki E¹⁵ ; Toure A¹⁶ ; Thome B¹⁷ Show All Authors

Singh JA^{1, 2, 3}
Kochhar S^{4, 5}
Wolff J⁶
Atuire C⁷
Bhan A⁸
Emanuel E⁹
Faden R¹⁰
Ghimire P¹¹
Greco D¹²
Ho C¹³
Moon S¹⁴
Shamsigooshki E¹⁵
Toure A¹⁶
Thome B¹⁷
Smith MJ¹⁸
Upshur REG¹⁹

Source: Vaccine Published:2022

Abstract

While the degree of COVID-19 vaccine accessibility and uptake varies at both national and global levels, increasing vaccination coverage raises questions regarding the standard of prevention that ought to apply to different settings where COVID-19 vaccine trials are hosted. A WHO Expert Group has developed guidance on the ethical implications of conducting placebo-controlled trials in the context of expanding global COVID-19 vaccine coverage. The guidance also considers alternative trial designs to placebo controlled trials in the context of prototype vaccines, modified vaccines, and next generation vaccines. © 2022

Related Docs

View other Related Docs

1. Recent Developments in Sars-Cov-2 Vaccines: A Systematic Review of the Current Studies, Reviews in Medical Virology (2023)

2. Safety and Immunogenicity of a Recombinant Receptor-Binding Domain-Based Protein Subunit Vaccine (Noora Vaccine™) Against Covid-19 in Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial, Journal of Medical Virology (2023)

3. The Perspective of Iranian Patients With Multiple Sclerosis on the Third Dose of Covid-19 Vaccine, Current Journal of Neurology (2022)

Experts (# of related papers)

View all Related Experts

Seyed Ahmad Seyed Alinaghi (5)

Nima Rezaei (2)

Style	Citing Format
MLA	Singh JA, et al.. "Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations." Vaccine, vol. 40, no. 14, 2022, pp. 2140-2149.
APA	Singh JA, Kochhar S, Wolff J, Atuire C, Bhan A, Emanuel E, Faden R, Ghimire P, Greco D, Ho C, Moon S, Shamsigooshki E, Toure A, Thome B, Smith MJ, Upshur REG (2022). Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations. Vaccine, 40(14), 2140-2149.
Chicago	Singh JA, Kochhar S, Wolff J, Atuire C, Bhan A, Emanuel E, Faden R, et al.. "Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations." Vaccine 40, no. 14 (2022): 2140-2149.
Harvard	Singh JA et al. (2022) 'Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations', Vaccine, 40(14), pp. 2140-2149.
Vancouver	Singh JA, Kochhar S, Wolff J, Atuire C, Bhan A, Emanuel E, et al.. Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations. Vaccine. 2022;40(14):2140-2149.
BibTex	@article{ author = {Singh JA and Kochhar S and Wolff J and Atuire C and Bhan A and Emanuel E and Faden R and Ghimire P and Greco D and Ho C and Moon S and Shamsigooshki E and Toure A and Thome B and Smith MJ and Upshur REG}, title = {Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations}, journal = {Vaccine}, volume = {40}, number = {14}, pages = {2140-2149}, year = {2022} }
RIS	TY - JOUR AU - Singh JA AU - Kochhar S AU - Wolff J AU - Atuire C AU - Bhan A AU - Emanuel E AU - Faden R AU - Ghimire P AU - Greco D AU - Ho C AU - Moon S AU - Shamsigooshki E AU - Toure A AU - Thome B AU - Smith MJ AU - Upshur REG TI - Who Guidance on Covid-19 Vaccine Trial Designs in the Context of Authorized Covid-19 Vaccines and Expanding Global Access: Ethical Considerations JO - Vaccine VL - 40 IS - 14 SP - 2140 EP - 2149 PY - 2022 ER -

Science Communicator Platform

Authors

Abstract